An Open-label, Single-dose, Clinical Trial of 68Ga-DOTATATE (GalioMedix™) PET-CT Scan for Diagnosis of Primary and Metastatic Somatostatin Receptor-positive Neuroendocrine Tumors (NETs)
Latest Information Update: 05 Apr 2023
At a glance
- Drugs Gallium 68-DOTATATE (Primary)
- Indications Neuroendocrine tumours
- Focus Diagnostic use
Most Recent Events
- 05 Oct 2020 Status changed from recruiting to completed.
- 12 May 2015 New trial record